Denali Therapeutics Q3'26 Results Expected November 3
Denali Therapeutics is scheduled to report Q3'26 results after market close on November 3. EPS is estimated at $(0.32).
Related stories
Shutterstock Founder Jon Oringer Returns as CEO; Hichame Assi Named President and COO
Shutterstock founder Jon Oringer returns as CEO, and Hichame Assi is named president and COO.
M impact | EQUITY | Oct 29, 2026, 10:45 PM UTC
TAL Education Group Reports Quarterly Results
TAL Education Group reported results for the quarter ended August 31.
M impact | EQUITY | Oct 29, 2026, 10:38 PM UTC
Business First Bancshares Approves Stock Repurchase Program Up to $30 Million
Business First Bancshares approved a stock repurchase program of up to $30 million.
L impact | EQUITY | Oct 29, 2026, 10:37 PM UTC
Osmond Resources Requests Trading Halt
L impact | EQUITY | Oct 29, 2026, 10:37 PM UTC
Exelixis reports quarterly results for period ended September 30
A machine-generated LSEG summary reports Exelixis' results for the quarter ended September 30.
M impact | EQUITY | Oct 29, 2026, 10:37 PM UTC
Twilio Reports Quarterly Results for Quarter Ended September 30
M impact | EQUITY | Oct 29, 2026, 10:37 PM UTC